Needham & Company Reiterates Akebia Therapeutics (AKBA) at Buy, Results From INNO2VATE Trial Support Approval of vadadustat
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $7.00 price target on Akebia Therapeutics (NASDAQ: AKBA), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
